News | Radiation Oncology | July 01, 2015

UC San Diego study suggests evolving chemotherapies improving results without early radiation therapy

low-grade brain tumors, gliomas, UC San Diego, survival rates up, adults

July 1, 2015 - Significant strides have been made in improving the survival of adult patients with low-grade gliomas, according to researchers at the University of California, San Diego School of Medicine. The scientists used clinical data collected over the past decade through a U.S. cancer registry for their research on the slow-growing yet deadly form of primary brain cancer. The findings are published July 1 by Neuro-Oncology: Clinical Practice.

Because of the rarity of low-grade gliomas, the disease remains understudied. The optimal management strategies for these tumors also remain controversial. Decisions of when and whether to administer radiation, what type of surgery to perform, and what type of chemotherapy to use, if any, varies widely among physicians.

"An understanding of how our treatments affect the survival of low-grade glioma patients will better enable us to help these patients," said senior author Clark C. Chen, M.D., Ph.D., vice chairman of research and academic development, Division of Neurosurgery, UC San Diego School of Medicine.

Using the Surveillance, Epidemiology, and End Results (SEER) database, a national cancer registry sponsored by the National Cancer Institute, Chen's team demonstrated that the median survival of patients afflicted with low-grade gliomas increased from 44 months (in 1999) to 57 months (in 2010). This is the first time that such increased survival has been reported.

The study suggests that the survival improvement is due to the development of more effective chemotherapies. Interestingly, the improved survival occurred despite a decreased use of radiation therapy at the time when low-grade glioma is first diagnosed.

"The decrease in the use of radiation started in 2005, concomitant to the publication of an important European randomized control study that demonstrated no significant survival benefit whether radiation was delivered at the time of diagnosis or later in the clinical course," said Xuezhi Dong, the study's first author.

While many previous studies suggest that complete excision of low-grade gliomas is associated with longer patient survival, this latest study found that only about a third of U.S. patients underwent complete surgical resection. Notably, this number remained unchanged throughout the past decade.

"The lack of improvement in surgical resection is likely limited by the availability of technologies, such as intra-operative MRI [magnetic resonance imaging], to allow surgeons to perform maximal surgical resection," said Bob S. Carter, M.D., Ph.D., chief of neurosurgery at UC San Diego Health. "The completion of an advanced surgical suite with an intra-operative MRI at Jacobs Medical Center in 2016 at UC San Diego Health will afford us an unprecedented opportunity to achieve maximal surgical resection of low-grade glioma and set forth new surgical standards for the care of this patient population."

For more information: www.som.ucsd.edu


Related Content

News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
News | Radiology Business

July 31, 2024 — The American Registry of Radiologic Technologists (ARRT) announced the three Registered Technologists (R ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 24, 2024 — Telix Pharmaceuticals Limited announced that the United States (U.S.) Food and Drug Administration (FDA) ...

Time July 24, 2024
arrow
News | Radiation Therapy

July 22, 2024 — RefleXion Medical, an external-beam theranostic oncology company, today announced that researchers from ...

Time July 22, 2024
arrow
News | ASTRO

July 18, 2024 — The members of the American Society for Radiation Oncology (ASTRO) recently elected five new officers to ...

Time July 18, 2024
arrow
News | PET-CT

July 16, 2024 — A new research paper was published in Oncotarget's Volume 15 on June 20, 2024, titled, “Comparison of ...

Time July 16, 2024
arrow
News | Digital Pathology

July 12, 2024 — AGFA HealthCare, a global leader in healthcare imaging management solutions, announced that Enterprise ...

Time July 12, 2024
arrow
Subscribe Now